Jump to main content
Jump to site search

Issue 11, 2018
Previous Article Next Article

Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent

Author affiliations

Abstract

Multidrug resistance (MDR) and metastasis are major causes of mortality in patients with cancer. We recently reported a bifendate derivative bearing a dibenzo[c,e]azepine scaffold (4i) as a P-gp and BCRP-medicated MDR reversal agent. As a continuation of the previous research, its ability to inhibit cancer metastasis was investigated in MDA-MB-231 cells in the present work. Wound-healing and chamber migration assays showed that 4i could significantly attenuate the migration of MDA-MB-231 cells. Additionally, 4i obviously suppressed the invasive activity of MDA-MB-231 cells, thus displaying potential anti-metastasis activity. Preliminary mechanism studies indicated that the anti-metastasis activity of 4i was associated with the inhibitory effect on the activity and expression of MMP-2 and MMP-9. These results, together with the previous findings, suggest that compound 4i could be a promising lead for the development of novel anti-cancer agents with anti-MDR and metastatic activities.

Graphical abstract: Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent

Back to tab navigation

Supplementary files

Publication details

The article was received on 11 Jun 2018, accepted on 17 Sep 2018 and first published on 17 Sep 2018


Article type: Research Article
DOI: 10.1039/C8MD00294K
Citation: Med. Chem. Commun., 2018,9, 1826-1830
  •   Request permissions

    Assessment of a bifendate derivative bearing a 6,7-dihydro-dibenzo[c,e]azepine scaffold as a potential anti-metastatic agent

    J. Qiu, W. Chen, Y. Jiang, J. Chen, Y. Zhang and X. Gu, Med. Chem. Commun., 2018, 9, 1826
    DOI: 10.1039/C8MD00294K

Search articles by author

Spotlight

Advertisements